Comparative Efficacy of ADM Hydrogel vs. Alginate Dressings in Chronic Trauma Wounds
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Injectable Acellular dermal matrix hydrogel, Alginate dressing.
- Who it may be relevant to
- Registry conditions: Trauma Wounds. Basic parameters: 18 years — 65 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Iran
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Randomized, Outcome Assessor-Blinded Clinical Trial Comparing the Efficacy of Acellular Dermal Matrix (ADM) Hydrogel Versus Alginate Dressings in the Treatment of Chronic Traumatic Wounds
Overview
The goal of this clinical trial is to find out whether a wound treatment made from acellular dermal matrix (ADM) gel can help heal chronic traumatic wounds more effectively than standard alginate dressings in adults aged 18 and older with wounds that have lasted more than 3 weeks. The main questions it aims to answer are: Does ADM gel reduce the size of chronic wounds more than alginate dressings after 12 weeks? Does ADM gel help wounds heal faster and improve quality of life for patients? Researchers will compare ADM gel to alginate dressings to see if the ADM gel leads to better healing results and fewer complications. Participants will: Be randomly assigned to receive either ADM gel or alginate dressing. Have the treatment applied directly to their cleaned wound. Attend weekly visits for up to 12 weeks for wound checks, measurements, and dressing changes.
Interventions
- Device Injectable Acellular dermal matrix hydrogel
An injectable, sterile acellular dermal matrix (ADM) gel derived from processed biological tissue, designed to promote healing in chronic wounds. The gel is injected directly onto the wound bed following standard debridement and serves as a biocompatible scaffold to support granulation tissue formation, epithelialization, and wound closure. After application, the wound is covered with a standard secondary dressing. Dressing changes are performed every 2 to 3 days or as clinically indicated. - Device Alginate dressing
A sterile, absorbent alginate wound dressing composed of natural polysaccharide fibers derived from seaweed. Following standard debridement, the alginate dressing is applied directly to the wound bed to manage exudate and maintain a moist wound environment conducive to healing. The dressing is covered with a secondary dressing and changed according to the manufacturer's instructions and clinical protocol.
Primary outcome measures
- Wound surface area (cm²) at Week 12, adjusted for baseline wound size [Time frame: Week 1 and 12]
Secondary outcome measures (5)
- Time to complete wound healing (100% epithelialization) [Time frame: Weekly up to 12 weeks]
- Rate of granulation tissue formation [Time frame: Weekly up to 12 weeks]
- Rate of wound epithelialization [Time frame: Weekly up to 12 weeks]
- Incidence of complications (infection, necrosis, bleeding) [Time frame: Up to 12 weeks]
- Quality of life score at Week 12 [Time frame: Weeks 1 and 12]
Eligibility criteria
Inclusion criteria
- Chronic trauma wounds persisting ≥3 weeks.
- Wound size between 4 and 20 cm² and depth ≤9 mm on the lower limbs.
- Willingness and ability to provide informed consent.
- Wounds without uncontrolled infection
Exclusion criteria
- Wounds with exposed bone.
- Current use of immunomodulators, corticosteroids, immunosuppressive or cytotoxic drugs.
- Pregnant individuals.
- Significant reduction (≥30%) of wound size during a 2-week run-in phase.
- Concurrent participation in another clinical trial involving drugs.
- Wounds with uncontrolled infection
- Allergy or hypersensitivity to components of ADM gel or alginate
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Single blind
- Primary purpose
- Treatment
Study locations
Iran · 1 center
- Alzahra hospital — Isfahan
Identifiers
NCT: NCT06978569 · IR.ARI.MUI.REC.1404.054